Research & Development


Our molecules have the potential to become the first approved JNK inhibitor treatment for BPS/IC directly treating inflammation.

Our molecules

KUSTE BIOPHARMA owns two JNK inhibitors previously extensively studied, and whose safety and efficacy have been demonstrated in a variety of therapeutic applications.

Our molecules have a strong safety profile, they have proven effects in local delivery and can therefore be used by the urology practitioner to treat BPS/IC.

Kuste Biopharma

129 rue Servient
69326 Lyon Cedex 3

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530

Retour en haut